Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug 31;477(7362):99-102.
doi: 10.1038/nature10358.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Caroline J Breitbach  1 , James Burke, Derek Jonker, Joe Stephenson, Andrew R Haas, Laura Q M Chow, Jorge Nieva, Tae-Ho Hwang, Anne Moon, Richard Patt, Adina Pelusio, Fabrice Le Boeuf, Joe Burns, Laura Evgin, Naomi De Silva, Sara Cvancic, Terri Robertson, Ji-Eun Je, Yeon-Sook Lee, Kelley Parato, Jean-Simon Diallo, Aaron Fenster, Manijeh Daneshmand, John C Bell, David H Kirn
Affiliations
Clinical Trial

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Caroline J Breitbach et al. Nature. .

Abstract

The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity. Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Res. 2001 Dec 15;61(24):8751-7 - PubMed
    1. J Clin Invest. 2005 Feb;115(2):379-87 - PubMed
    1. AJR Am J Roentgenol. 2004 Dec;183(6):1619-28 - PubMed
    1. Nat Clin Pract Oncol. 2007 Feb;4(2):101-17 - PubMed
    1. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7544-9 - PubMed

Publication types

MeSH terms

-